APDN Stock Overview
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Applied DNA Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.34 |
52 Week High | US$1.86 |
52 Week Low | US$0.31 |
Beta | 0.094 |
1 Month Change | -31.24% |
3 Month Change | -45.44% |
1 Year Change | -67.01% |
3 Year Change | -95.02% |
5 Year Change | -98.58% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%
Dec 20Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?
Jan 01Applied DNA climbs 51% after winning large purchase order
Oct 10Applied DNA stock rises 12% on launching monkeypox testing service in New York
Sep 06Applied DNA adds 17% as company seeks approval for monkeypox test in New York
Aug 19Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
Aug 17Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise
Aug 09Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test
Aug 02Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19
Jul 25News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
May 18Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Deliver On Growth Plans?
Sep 17Applied DNA's LinearDNA COVID-19 vaccine booster yields 5-fold increase in neutralizing antibody in felines
May 06Shareholder Returns
APDN | US Life Sciences | US Market | |
---|---|---|---|
7D | -4.7% | -4.1% | -3.2% |
1Y | -67.0% | -6.7% | 19.3% |
Return vs Industry: APDN underperformed the US Life Sciences industry which returned -6.7% over the past year.
Return vs Market: APDN underperformed the US Market which returned 19.3% over the past year.
Price Volatility
APDN volatility | |
---|---|
APDN Average Weekly Movement | 12.1% |
Life Sciences Industry Average Movement | 7.0% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APDN's share price has been volatile over the past 3 months.
Volatility Over Time: APDN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | 54 | James Hayward | www.adnas.com |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Applied DNA Sciences, Inc. Fundamentals Summary
APDN fundamental statistics | |
---|---|
Market cap | US$5.83m |
Earnings (TTM) | -US$7.29m |
Revenue (TTM) | US$9.00m |
0.6x
P/S Ratio-0.8x
P/E RatioIs APDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
APDN income statement (TTM) | |
---|---|
Revenue | US$9.00m |
Cost of Revenue | US$5.61m |
Gross Profit | US$3.39m |
Other Expenses | US$10.67m |
Earnings | -US$7.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.43 |
Gross Margin | 37.65% |
Net Profit Margin | -81.00% |
Debt/Equity Ratio | 0% |
How did APDN perform over the long term?
See historical performance and comparison